--- title: "Hong Kong stocks \"synthetic death\" first stock IMPACT THERAP-B first listing stock price doubled" type: "News" locale: "en" url: "https://longbridge.com/en/news/286361925.md" description: "IMPACT THERAP-B was listed on the Hong Kong stock market, becoming the first innovative oncology drug company based on the \"synthetic lethality\" mechanism. On its first day of trading, the stock price surged by 108.26%, closing at HKD 41.86. This IPO globally offered approximately 41.98 million shares, raising a net amount of HKD 759 million, with the public offering portion oversubscribed by more than 2,281 times. Although the company is still in a state of significant losses, with a projected net loss of HKD 296 million in 2025, its core product, Senaparib, has been approved and included in the medical insurance catalog, becoming the focus of market attention" datetime: "2026-05-14T05:25:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286361925.md) - [en](https://longbridge.com/en/news/286361925.md) - [zh-HK](https://longbridge.com/zh-HK/news/286361925.md) --- # Hong Kong stocks "synthetic death" first stock IMPACT THERAP-B first listing stock price doubled _Impact Therapeutics is the first tumor innovative drug company in the Hong Kong stock market based on the "Synthetic Lethality" mechanism. Its core product, Senaparib, has been approved in China and included in the medical insurance catalog._ #### **Key Points:** - Impact Therapeutics was highly sought after by investors during the fundraising phase, with the public offering portion oversubscribed by over 2,281 times. - The company is still in a state of significant loss, with a net loss of 296 million yuan in 2025, and revenue of 38.25 million yuan is still unable to cover high R&D expenses. Molly As cancer treatment enters the era of precision medicine, new therapies represented by "Synthetic Lethality" have become a hotspot for capital. On May 13, the Hong Kong stock market welcomed the "first stock of synthetic lethality tumor drugs," and as a leading company in this field, **Nanjing Impact Therapeutics Co., Ltd.** (7630.HK) surged 108.26% on its first day of listing, closing at HKD 41.86, attracting market attention. Impact Therapeutics' IPO **global offering** consisted of approximately 41.98 million H shares, with an issue price of HKD 20.1 per share, raising a net amount of HKD 759 million. The company was highly sought after by investors during the fundraising phase, with the public offering portion oversubscribed by over 2,281 times. The IPO was co-sponsored by Goldman Sachs and China International Capital Corporation. Founded in 2009, Impact Therapeutics is an innovative pharmaceutical company focused on developing precision anti-cancer therapies based on the "Synthetic Lethality" mechanism. "Synthetic Lethality" is a biological genetic phenomenon where two non-lethal genes or proteins can mutate individually without causing cell death; however, if both genes fail simultaneously, it leads to cell death. Cancer cells typically carry a specific gene mutation, and inhibiting another gene can lead to the death of cancer cells. PARP inhibitors are the first successful drugs based on the synthetic lethality mechanism, used to treat tumors with BRCA gene mutations, such as ovarian and breast cancer. According to the prospectus, Impact Therapeutics' core product is a self-developed PARP1/2 inhibitor, Senaparib. As the company's first commercialized product, Senaparib is expected to be approved for marketing in China in January 2025 for maintenance treatment in patients with advanced ovarian cancer after first-line chemotherapy. Clinical data show that Senaparib can reduce the risk of disease progression or death by 57%, and its efficacy is not limited by BRCA gene mutation status, achieving benefits for the "entire population." In December 2025, Senaparib will be included in the national medical insurance catalog, laying the foundation for its market expansion. Through cooperation with East China Pharmaceutical, the product has already covered over 900 medical institutions in China. In addition to the commercialized Senaparib, the company also has 11 drugs in the clinical stage, including next-generation PARP1 selective inhibitors and ATR inhibitors. #### **Shareholder Lineup "Star-Studded"** As a newly commercialized biopharmaceutical company, Impact Therapeutics is still in a phase of continuous losses. The prospectus shows that in 2024 and 2025, Impact Therapeutics' operating revenue will be 33.547 million yuan and 38.251 million yuan, respectively, coming from a significant external licensing deal and the revenue generated after Senaparib's launch in 2025 020 million yuan in sales revenue. During the same period, the company incurred losses of 255 million yuan and 296 million yuan, primarily due to high research and development expenses, with cumulative R&D investment reaching 379 million yuan over two years. As of the end of 2025, the company's cash and cash equivalents amounted to 259 million yuan, which, at the current "burn rate," can only sustain operations for about a year, making IPO financing urgent. Of the funds raised in this IPO, approximately 51% will be used for the further clinical development and commercialization of Senaparib, and 31% for the clinical development of other key products. This indicates that the company still needs to continue investing heavily to advance its pipeline, and the profitability inflection point is far from being reached. The synthetic lethality sector in which IMPACT THERAP-B operates has broad prospects, with reports cited in the prospectus indicating that the global synthetic lethality market is expected to grow from USD 4.3 billion in 2024 to USD 8.7 billion by 2029. However, market competition should not be underestimated. In the PARP inhibitor market, AstraZeneca's Olaparib and HengRui Medicine's Furazoparib have already established a first-mover advantage. Although Senaparib has differentiated characteristics with "full population" coverage, it still faces significant challenges in catching up in a fiercely competitive environment. Before going public, IMPACT THERAP-B had completed multiple rounds of financing, attracting investments from well-known institutions such as Eli Lilly Asia Fund, Tencent, Junshi Biosciences, and WuXi AppTec, with a "star-studded" list of shareholders. In this IPO, six cornerstone investors were introduced, with a total subscription amount of approximately USD 35.87 million. Among them are not only endorsements from old shareholders like Tencent and Eli Lilly Asia Fund but also support from public funds like Ruiyuan Fund and Jiangbei New District State-owned Assets. Based on the IPO issue price, IMPACT THERAP-B corresponds to a market value of approximately HKD 6.007 billion. If calculated based on its 2025 revenue, its price-to-sales ratio reaches about 145 times, placing it at a high position among the 18A biotech companies characterized by "high valuations." As its core product Senaparib is expected to gain volume after entering the medical insurance system in 2026, IMPACT THERAP-B's high gross margin of 95.9% is likely to decline due to adjustments in medical insurance payment prices. Against the backdrop of high valuations and potential gross margin adjustments, whether IMPACT THERAP-B can achieve leapfrog revenue growth becomes key to digesting the current valuation, warranting close attention from investors ### Related Stocks - [07630.HK](https://longbridge.com/en/quote/07630.HK.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [03908.HK](https://longbridge.com/en/quote/03908.HK.md) - [000963.CN](https://longbridge.com/en/quote/000963.CN.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [600276.CN](https://longbridge.com/en/quote/600276.CN.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [00700.HK](https://longbridge.com/en/quote/00700.HK.md) - [01877.HK](https://longbridge.com/en/quote/01877.HK.md) - [688180.CN](https://longbridge.com/en/quote/688180.CN.md) - [603259.CN](https://longbridge.com/en/quote/603259.CN.md) - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [601995.CN](https://longbridge.com/en/quote/601995.CN.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [TCEHY.US](https://longbridge.com/en/quote/TCEHY.US.md) - [80700.HK](https://longbridge.com/en/quote/80700.HK.md) - [HTCD.SG](https://longbridge.com/en/quote/HTCD.SG.md) - [TCTZF.US](https://longbridge.com/en/quote/TCTZF.US.md) - [02359.HK](https://longbridge.com/en/quote/02359.HK.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) ## Related News & Research - [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md) - [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md) - [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md) - [Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026](https://longbridge.com/en/news/286795160.md) - [12:36 ETDiagnostics Direct LLC Wins Innovation Award from Johns Hopkins](https://longbridge.com/en/news/286945918.md)